Leadership Committee

TONI CHOUEIRI, M.D.
Director, Lank Center for Genitourinary Oncology

HANS HAMMERS, M.D., Ph.D
Associate Professor of Internal Medicine, Division of Hematology-Oncology

SUMANTA PAL, M.D.
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research

BRYAN LEWIS
President

SUSAN POTEAT
Medical Science Liaison

PEDRO BARATA, M.D., M.Sc
Assistant Professor of Medicine

STEPHANIE BERG, DO
Assistant Professor of Medicine

MEHMET BILEN, M.D.
Director, Genitourinary Medical Oncology Program

BRAD MCGREGOR, M.D.
Clinical Director, Lank Center for Genitourinary Oncology

RANA MCKAY, M.D.
Associate Professor of Medicine

SUMANTA PAL, M.D.
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research

FABIO A SCHUTZ, M.D.
Oncologista Clinico
DoD / KCRP Session Committee

MARIA CARLO, M.D.
Associate Professor of Medicine

ERIC JONASCH, M.D.
Professor, Department of Genitourinary Medical Oncology

MEDHI MOLLAPOUR, Ph.D
Professor of Urology

TIAN ZHANG, M.D.
Assistant Professor of Medicine
Communications Committee

NEERAJ AGARWAL, M.D.
Senior Director of Clinical Research Innovation

DAVID BRAUN, M.D., Ph.D
Assistant Professor of Medicine

GIL MORGAN, M.D.
Medical Oncologist

PAVLOS MSAOUEL, M.D., Ph.D
Assistant Professor, Department of Genitourinary Medical Oncology

FABIO SCHUTZ, M.D.
Oncologista Clinico

QING ZHANG, Ph.D
Associate Professor, Department of Pathology

TIAN ZHANG, M.D.
Assistant Professor of Medicine

ADRIAN HAYES
Communications Consultant
Featured Speakers

DREW PARDOLL, M.D., PhD

SUZANNE TOPALIAN, M.D.
Associate Professor, Bloomberg-Kimmel Institute for Cancer Immunotherapy

ANDREW SEWELL, PhD

ANDREW SEWELL, PhD
Professor, Division of Infection and Immunity
The research team at Cardiff, led by Professor Sewell, has discovered unconventional T-cells equipped with a new type of T-cell receptor (TCR) which recognizes and kills most human cancer types while ignoring healthy cells. The discovery holds out the tantalizing possibility of a universal approach to killing cancer. The Nature Immunology article on this TCR found it recognized and killed most human cancer types via the monomorphic MHC class I-related protein, MR1.
The hope is this new TCR may provide the scientific community with a different route to target and destroy a wide range of cancers in all patients, opposed to the widely known therapy, CAR-T, which is personalized to each patient and targets only a few types of cancers and has not been successful in solid tumors. Research has shown that TCR kills cancer cells in the lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney, and cervix while ignoring healthy cells. This approach is now in promising early clinical trials with other cancers.
Dr. Sewell will open the Friday morning Immunotherapy session talks and discussions. We’re looking forward to learning more about the progress of this treatment which could someday be available to kidney cancer patients.

DREW PARDOLL, M.D., PhD
Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Dr. Pardoll is the inventor of numerous immunotherapy vaccines and has published over 300 articles related to cancer vaccines, gene therapies, and cancer prevention technologies.
His lab focuses on T-cell responses and approaches to modify these responses for targeted immunotherapy. These novel therapies target neoantigens, which could revolutionize the treatment of cancer patients in the decades to come by fulfilling the promise of a personalized, individual treatment.
In this video, “A Future Immune to Cancer,” Dr. Pardoll discusses his work with immunology. He also speaks about the importance of advocating for and donating to research funding.

SUZANNE TOPALIAN, M.D.
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
In the laboratory and in the clinic, Dr. Topalian serves as a physician-scientist whose research interests focus on cancer immunology and immunotherapy. She has published over 100 original research articles and reviews in this field and is internationally recognized for this work. Dr. Topalian’s research continues to focus on immune checkpoints, such as PD-1 alone and in combinations.
Checkpoint research has broadly changed the options for cancer care in many cancers including kidney cancer, and for some patients, it is offering long-term responses.
We’re honored to have Dr Topalian and her husband and collaborator Drew Pardoll discussing new directions in immunotherapy at Thursday’s “Fireside Chat” to open KCRS22.
session 1
Tumor Evolution

ERIC JONASCH, M.D.
Professor, Department of Genitourinary Medical Oncology
session 2
Innovative Non-Immune Therapy

ERIC JONASCH, M.D.
Professor, Department of Genitourinary Medical Oncology
session 3
Oral Abstracts

RANA MCKAY, M.D.
Associate Professor of Medicine

SUMANTA PAL, M.D.
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
session 4
DoD Immunotherapy

ESRA AKBAY, Ph.D
UT Southwestern Medical Center
Assistant Professor, Department of Pathology

DAVID BRAUN, M.D., Ph.D
Yale School of Medicine
Assistant Professor of Medicine

SIDI CHEN, Ph.D
Yale University
Assistant Professor

HANS HAMMERS, M.D., Ph.D
Associate Professor of Internal Medicine, Division of Hematology-Oncology

ANDREW SEWELL, PhD
Cardiff University
Professor, Division of Infection and Immunity
session 5
Clinical & Scientific Updates in Kidney Cancer

TONI CHOUEIRI, M.D.
Director, Lank Center for Genitourinary Oncology

RANA MCKAY, M.D.
Associate Professor of Medicine

SUMANTA PAL, M.D.
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research

TOM POWLES, MBBS, MRCP, M.D.
Director, Barts Cancer Centre

BRIAN RINI, M.D.
Chief of Medical Trials

MARTIN VOSS, M.D.
Memorial Sloan Kettering Cancer Center
Clinical Director, Genitourinary Medical Oncology Service
session 6
Rapid Abstracts

RANA MCKAY, M.D.
University of California, San Diego
Associate Professor of Medicine

SUMANTA PAL, M.D.
Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
Sponsorship Opportunities
The Kidney Cancer Research Summit is funded through sponsors and partnerships. The meeting is also funded by KidneyCAN's grassroots supporters, a nationwide network of kidney cancer patients, caregivers, and family members who are committed to accelerating cures for kidney cancer.
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program).
For details about sponsorship opportunities at KCRS22 and other KidneyCAN projects, please contact us.

KidneyCAN's mission is to accelerate cures for kidney cancer.
Learn more.
KidneyCAN | 8327 Germantown Avenue | Philadelphia | PA 19118